Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126064643 | 12606464 | 3 | F | 201506 | 20160905 | 20160729 | 20160909 | EXP | CN-GLAXOSMITHKLINE-CN2016GSK107860 | GLAXOSMITHKLINE | 58.00 | YR | F | Y | 58.00000 | KG | 20160909 | CN | CN | CN |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126064643 | 12606464 | 1 | PS | SERETIDE | FLUTICASONE PROPIONATESALMETEROL XINAFOATE | 1 | Respiratory (inhalation) | UNK | Y | 21077 | INHALATION POWDER | ||||||||
126064643 | 12606464 | 2 | SS | SERETIDE | FLUTICASONE PROPIONATESALMETEROL XINAFOATE | 1 | UNK | Y | 21077 | INHALATION POWDER | |||||||||
126064643 | 12606464 | 3 | SS | SERETIDE | FLUTICASONE PROPIONATESALMETEROL XINAFOATE | 1 | 1 PUFF(S), Z | Y | RV2H | 21077 | 1 | DF | INHALATION POWDER | ||||||
126064643 | 12606464 | 4 | SS | SERETIDE | FLUTICASONE PROPIONATESALMETEROL XINAFOATE | 1 | Respiratory (inhalation) | UNK | Y | 21077 | INHALATION POWDER | ||||||||
126064643 | 12606464 | 5 | SS | SERETIDE | FLUTICASONE PROPIONATESALMETEROL XINAFOATE | 1 | Respiratory (inhalation) | 1 PUFF(S), SINGLE | Y | 21077 | 1 | DF | INHALATION POWDER | ||||||
126064643 | 12606464 | 6 | SS | SERETIDE | FLUTICASONE PROPIONATESALMETEROL XINAFOATE | 1 | Respiratory (inhalation) | 1 PUFF(S), BID | Y | 21077 | 1 | DF | INHALATION POWDER | BID | |||||
126064643 | 12606464 | 7 | SS | SERETIDE | FLUTICASONE PROPIONATESALMETEROL XINAFOATE | 1 | 1 PUFF(S), QD | Y | 21077 | 1 | DF | INHALATION POWDER | QD | ||||||
126064643 | 12606464 | 8 | SS | SERETIDE | FLUTICASONE PROPIONATESALMETEROL XINAFOATE | 1 | 1 PUFF(S), EVERY OTHER DAY | Y | 21077 | 1 | DF | INHALATION POWDER | |||||||
126064643 | 12606464 | 9 | SS | VENTOLIN HFA | ALBUTEROL SULFATE | 1 | Respiratory (inhalation) | 1 PUFF(S), SINGLE | U | 0 | 1 | DF | |||||||
126064643 | 12606464 | 10 | C | AMINOPHYLLINE. | AMINOPHYLLINE | 1 | 1 DF, QD | Y | 0 | 1 | DF | TABLET | QD | ||||||
126064643 | 12606464 | 11 | C | KETOTIFEN | KETOTIFEN | 1 | 1 DF, QD | Y | 0 | 1 | DF | TABLET | QD |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
126064643 | 12606464 | 1 | Asthma |
126064643 | 12606464 | 9 | Asthma |
126064643 | 12606464 | 10 | Asthma |
126064643 | 12606464 | 11 | Asthma |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
126064643 | 12606464 | HO |
126064643 | 12606464 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
126064643 | 12606464 | Asthma | |
126064643 | 12606464 | Drug ineffective | |
126064643 | 12606464 | Hypersensitivity | |
126064643 | 12606464 | Nasopharyngeal cancer | |
126064643 | 12606464 | Product use issue | |
126064643 | 12606464 | Weight decreased | |
126064643 | 12606464 | Wheezing |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
126064643 | 12606464 | 1 | 2013 | 0 | ||
126064643 | 12606464 | 2 | 201606 | 20160710 | 0 | |
126064643 | 12606464 | 3 | 20160725 | 0 | ||
126064643 | 12606464 | 4 | 20160831 | 0 | ||
126064643 | 12606464 | 5 | 20160904 | 0 |